<DOC>
	<DOCNO>NCT02271438</DOCNO>
	<brief_summary>The purpose study assess safety tolerability ibrutinib , compare pharmacokinetics ibrutinib single oral administration 840 mg 1680 mg ass effect single dose ibrutinib QT/QTc interval electrocardiogram ( ECG ) healthy adult .</brief_summary>
	<brief_title>A Study Evaluate Effects Ibrutinib Cardiac Repolarization Healthy Participants</brief_title>
	<detailed_description>The study consist 2 part : Part 1 Part 2 . Part 1 open-label ( medical research study participant researcher tell treatment participant receive ) , single-center , 2-period , sequential design part . It consist Screening phase ( Day-21 -2 ) , Treatment Period 1 Treatment Period 2 . In treatment period 1 , 8 participant include two woman receive 840 milligram ( mg ) ibrutinib capsule + 6 placebo capsule . In treatment period 2 , participant receive 1680 mg ibrutinib capsule . Treatment period separate Washout period le 7 day . A high-fat breakfast provide 2 hour dose . Blood sample collect dose pharmacokinetic assessment . Part 2 randomize ( study medication assign chance ) , placebo ( inactive substance compare medication test whether medication real effect clinical study ) positive-controlled ( participant assign either recognize effective treatment study medication ) , double-blind ( neither physician participant know treatment participant receives ) , single dose , 4-way crossover ( medication provide participant different sequence ) part . Participants receive either 4 treatment : Treatment A ( Ibrutinib 1680 mg + moxifloxacin-matching placebo ) ; Treatment B ( Ibrutinib 840 mg+ ibrutinib-matching placebo + moxifloxacin-matching placebo ) ; Treatment C ( ibrutinib-matching placebo + moxifloxacin-matching placebo ) ; Treatment D : ( moxifloxacin 400 mg + ibrutinib-matching placebo ) . Each treatment period separate Washout period le 7 day . Electrocardiogram ( ECG ) record . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Must sign inform consent document indicate understand purpose study procedure Must body mass index ( BMI ) 18 30 kg/m^2 , inclusive Must body weight less 50 kg Must blood pressure 90 140 mmHg inclusive , systolic , high 90 mmHg diastolic screen Must average triplicate 12lead ECG recording , complete within 5 minute total , consistent normal cardiac conduction function History current clinically significant medical illness Clinically significant abnormal physical examination , vital sign 12 lead electrocardiogram History clinically relevant heart rhythm disturbance include atrial , junctional , reentry , ventricular tachycardia , heart block Use prescription nonprescription medication ( include vitamin herbal supplement Donated blood blood product substantial loss blood within 3 month screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Ibrutinib</keyword>
	<keyword>Moxifloxacin</keyword>
	<keyword>Cardiac Repolarization</keyword>
	<keyword>Electrocardiogram</keyword>
	<keyword>QTc interval</keyword>
</DOC>